BioCryst Pharmaceuticals to Announce Fourth Quarter 2009 Financial Results on February 4, 2010

Jan 21, 2010, 07:00 ET from BioCryst Pharmaceuticals

BIRMINGHAM, Ala., Jan. 21 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its fourth quarter 2009 financial results will be released on Thursday, February 4, 2010.  BioCryst will host a conference call and Web cast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update on the Company's programs.  The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Stuart Grant, Chief Financial Officer and Dr. William P. Sheridan, Chief Medical Officer.

The Web cast can be accessed by logging onto  Please connect to the Web site at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed.  To participate in the conference call, please dial 1-888-206-4913 (United States) or 1-913-312-9315 (International).  No passcode is needed for the call.  The audio portion of the Web cast will be archived and available for replay for at least 14 days.

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases.  BioCryst has progressed two novel compounds into late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL).  Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians.  For more information, please visit the Company's Web site at

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.  Please refer to the documents BioCryst files periodically with the SEC and located at


SOURCE BioCryst Pharmaceuticals